P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Bibliographic Details
Main Authors:	Darrell White, Muhamed Baljevic, Gary Schiller, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane Van Domelen, Ohad Bentur, Sumit Madan
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970832.89903.8f

Similar Items

PB2106: REAL-WORLD SAFETY AND EFFECTIVENESS OF SELINEXOR-BASED REGIMENS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT RENAL IMPAIRMENT
by: James Niblock, et al.
Published: (2023-08-01)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
by: Juan Du, et al.
Published: (2023-08-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
by: Muhamed Baljevic, et al.
Published: (2022-11-01)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
by: Adam F. Binder, et al.
Published: (2023-10-01)

PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
by: Tassia Cristina Decimoni, et al.
Published: (2023-08-01)

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
by: A. Bobin, et al.
Published: (2022-06-01)

The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
by: İlker Çorapçı, et al.
Published: (2004-03-01)

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)
by: Hamid Ehsan, et al.
Published: (2024-03-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
by: Georg Jeryczynski, et al.
Published: (2021-11-01)

P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
by: Nizar J Bahlis, et al.
Published: (2023-08-01)

Annual technical report (l982)
by: Yang, T.F., et al.
Published: (2015)

The Effects of Once-Weekly Alendronate 70 mg, Risedronate 35 mg and Raloxifene 60 mg Daily in the Treatment of Postmenopausal Osteoporosis in Turkish Population
by: Mesut Öktem, et al.
Published: (2007-04-01)

Efficacy and safety of terbinafine 500 mg once daily in patients with dermatophytosis
by: P Ravindra Babu, et al.
Published: (2017-01-01)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
by: Notter Marianne, et al.
Published: (2008-03-01)

IS982 and kin: new insights into an old IS family
by: Nancy Fayad, et al.
Published: (2020-07-01)

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
by: F Schjesvold, et al.
Published: (2023-05-01)

Pomalidomide-induced hypothyroidism
by: Sulaiman Haji Ali, et al.
Published: (2017-12-01)

COMPARISON OF EFFICACY AND SAFETY SILODOSIN 8 MG ONCE DAILY AND SILODOSIN 4 MG TWICE DAILY IN BPH PATIENTS WITH LUTS
by: Ramzie Nendra Diansyah, et al.
Published: (2019-01-01)

Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
by: Cowen, P, et al.
Published: (2005)

PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Katja Weisel, et al.
Published: (2023-08-01)

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY
by: Vania Hungria, et al.
Published: (2023-08-01)

Selinexor and COVID-19: The Neglected Warden
by: Gomaa Mostafa-Hedeab, et al.
Published: (2022-04-01)

Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01)

Bumped pomalidomide-based PROTACs
by: Huijuan Guo
Published: (2024-02-01)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
by: Paula Rackoff
Published: (2009-05-01)

Treatment of multiple myeloma with selinexor: a review
by: Qianlei Huang, et al.
Published: (2024-01-01)

Once-yearly zoledronic acid 5 mg therapy for osteoporosis: a focus on a patient
by: Irina Aleksandrovna Baranova, et al.
Published: (2011-09-01)

Once-yearly zoledronic acid 5 mg therapy for osteoporosis: a focus on a patient
by: Irina Aleksandrovna Baranova, et al.
Published: (2011-09-01)

Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
by: Yaman Alali, et al.
Published: (2021-12-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
by: Patrick J. Stiff, et al.
Published: (2023-09-01)

Selinexor: Targeting a novel pathway in multiple myeloma
by: Clifton C. Mo, et al.
Published: (2023-08-01)

Pomalidomide-based therapy for extramedullary multiple myeloma
by: Yating Li, et al.
Published: (2022-12-01)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
by: Gowin KL, et al.
Published: (2015-04-01)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
by: Yan-Rou Tsai, et al.
Published: (2019-04-01)

Pomalidomide induced lupus type hypersensitivity reaction
by: Chinmay Jani, et al.
Published: (2021-03-01)

The Palermo Qurʾān (AH373/982–83AD) and its historical context
by: Johns, J
Published: (2017)

Sickle cell disease and pregnancy profile of complicated malaria in 982 pregnancies in Kinshasa
by: Tite Minga Mikobi, et al.
Published: (2022-01-01)